Jeil Pharmaceutical Co., Ltd.
Records under this name other than the patents Jeil Pharmaceutical Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.
Showing 1 to 9 of 9 · Back to Jeil Pharmaceutical Co., Ltd.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,260,049 | Attenuated Reovirus Formerly held In force · High confidence | In force | High confidence | |
| US 8,492,149 | Efficient generation of neural progenitors, neurons, and dopaminergic neurons from human embryonic stem cells Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,369,171 | Attenuated reoviruses for selection of cell populations Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,906,395 | Pharmaceutical composition in which solubility of partially soluble tricyclic derivative is improved Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,464,919 | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,898,164 | Method for producing pluripotent stem cell-derived spherical neural mass having suppressed teratoma formation Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,742,160 | Method for preparing tricyclic derivatives Formerly held Lapsed on the fee record Ended Jun 3, 2026 · USPTO record | Lapsed on the fee record | Ended Jun 3, 2026 | USPTO record |
| US 8,334,277 | {4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}phosphate or a pharmaceutically acceptable salt thereof, a production method therefor and a pharmaceutical composition for preventing and treating central nervous system disorders containing the same as an active component Lapsed on the fee record Ended Dec 18, 2020 · USPTO record | Lapsed on the fee record | Ended Dec 18, 2020 | USPTO record |
| US 5,859,016 | Memory enhancing and anti-dementia agent containing dehydroevodiamine HC1 as active ingredient Formerly held Term ended Term ended no later than Jan 12, 2019 · Low confidence | Term ended | Term ended no later than Jan 12, 2019 | Low confidence |